Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial is a research paper published in Cancer Cell (2020). On theSindex it has a DataRank of 4.8. It has been cited 398 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.898
From this paper's citation signal
Citation Network Contribution
3.9
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
National Institutes of Health
Grant: P30 CA016672
American Anthropological Association
Parker Institute for Cancer Immunotherapy
Bayer Corporation
Meso Scale Diagnostics
Astellas Pharma US
Janssen Biotech
Merck
National Cancer Institute
Prostate Cancer Foundation
Amgen
Pfizer
Breast Cancer Now
Bristol-Myers Squibb
Roche
Exelixis
Ono Pharmaceutical
AstraZeneca
Bristol-Myers Squibb Canada
Genentech
Sanofi
FWCI
17.34
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals